Clinical Trial Update: Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Early-phase clinical trial investigating a combination of azacitidine, venetoclax, and eganelisib to target PI3K gamma in patients with acute myeloid leukemia; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Eganelisib (eganelisib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Jacqueline Garcia, MD | Conditions: Leukemia, Myeloid, Leukemia | Phase 1 | Status: NOT_YET_RECRUITING